Replies to post #385433 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The UCLA lab only makes whatever it makes to study a specific scientific premise. They also are not licensees or owners of Flaskworks technology. So highly unlikely there. This is also consistent with what I have said repeatedly about licensing agreements. They retain the right to study DCVax, and even t improve it, and typically the benefit of all this work flows to the licensee, NWBO.

At Sawston, I expect the company will follow its plan, focusing first on certifying current production technology while they work as fast as possible to validate the new technology. I am sure they will be as anxious as anyone to open up the scale of production ASAP. But it’s new. So they will be certifying it from scratch. They already had a baseline of procedures for the current production method. And certification was still complex. So I think it can take a little more time than people often wish to do these things.

[Doc logic]

skitahoe,

Direct is already manufactured in a fully closed system. The hang up has always been with L manufacturing, getting L across the finish line and getting regulators up to speed with the entire platform. Imagine what happens if an activated/matured DC vaccine is considered the same as all other activated/matured DC vaccines safety wise and target wise when using similar methods, purity and final DC characteristics as a basis for doing so. Best wishes.